Somewhat Favorable News Coverage Somewhat Unlikely to Affect Tandem Diabetes Care (TNDM) Stock Price
News stories about Tandem Diabetes Care (NASDAQ:TNDM) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.5998520911755 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Tandem Diabetes Care Announces Issuance of Patent Related to Automated Insulin Delivery Technology (finance.yahoo.com)
- Tandem Diabetes Care Inc (TNDM) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Tandem Diabetes Care (TNDM) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)
- Tandem Diabetes Care (TNDM) Upgraded to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Zacks: Brokerages Anticipate Tandem Diabetes Care Inc (TNDM) Will Announce Quarterly Sales of $34.36 Million (americanbankingnews.com)
TNDM has been the subject of several research reports. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, November 1st. Robert W. Baird reiterated a “hold” rating and set a $3.00 price objective on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Piper Jaffray Companies reiterated a “hold” rating and set a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Tandem Diabetes Care currently has a consensus rating of “Hold” and a consensus target price of $11.29.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.74) by $0.65. Tandem Diabetes Care had a negative net margin of 79.45% and a negative return on equity of 1,177.11%. The company had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.92 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The firm’s quarterly revenue was up 119.7% on a year-over-year basis. equities analysts predict that Tandem Diabetes Care will post -15.37 EPS for the current fiscal year.
In other news, CEO Kim D. Blickenstaff acquired 285,700 shares of the business’s stock in a transaction on Friday, October 13th. The stock was bought at an average price of $3.50 per share, with a total value of $999,950.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 20.90% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-tandem-diabetes-care-tndm-stock-price/1766345.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.